Delayed introduction of sirolimus in paediatric intestinal transplant recipients: indications and long‐term benefits
- 26 June 2021
- journal article
- research article
- Published by Frontiers Media SA in Transplant International
- Vol. 34 (10) , 1895-1907
Abstract
Aim To review our experience using sirolimus in a single center pediatric intestinal transplantation cohort. Patient/Methods Intestinal transplant patients with more than 3 months follow-up were divided in two groups according to their immunosuppression regimen: tacrolimus, (TAC group, n=45 grafts) or sirolimus (SRL group, n=38 grafts), which included those partially or completely converted from tacrolimus to sirolimus. The indications to switch were tacrolimus side-effects and immunological complications. Survival and complications were retrospectively analyzed comparing both groups. Results SRL was introduced 9 months (0 months-16.9 years) after transplant. The main cause for conversion was worsening renal function (45%), followed by hemolytic anemia (21%) and graft-versus-host-disease (16%). Both groups showed a similar overall patient/graft survival (p=0.76/0.08) and occurrence of rejection (24%/17%, p=0.36). Immunological complications did not recur after conversion. Renal function significantly improved in most SRL patients. After a median follow-up of 65.17 months, 28/46 survivors were on SRL, 26 with monotherapy, with good graft function. Conclusions Over one-third of our patients eventually required SRL conversion that allowed to improve their kidney function and immunological events, without entailing additional complications or survival impairment. Further trials are warranted to clarify the potential improvement of the standard tacrolimus maintenance by sirolimus conversion or addition.Keywords
This publication has 46 references indexed in Scilit:
- Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant ConsortiumTransplantation, 2011
- Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an updateCurrent Opinion in Hematology, 2010
- Autoimmune cytopaenia after paediatric intestinal transplantation: a case seriesTransplant International, 2010
- Immune monitoring in small bowel transplantationCurrent Opinion in Organ Transplantation, 2010
- Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT TrialTransplantation, 2009
- Chronic Kidney Disease—A Common and Serious Complication After Intestinal TransplantationTransplantation, 2008
- Sirolimus for solid organ transplantation in childrenPediatric Transplantation, 2005
- Pharmacokinetics of Sirolimus and Tacrolimus in Pediatric Transplant PatientsAmerican Journal of Transplantation, 2004
- Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantationTransplantation, 2004
- Sirolimus in pediatric gastrointestinal transplantation: The use of sirolimus for pediatric transplant patients with tacrolimus‐related cardiomyopathyPediatric Transplantation, 2000